Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03253289 · ClinicalTrials.gov registry record · Phase 1
Meclizine for Hepatocellular Carcinoma
A Phase 1 study of Carcinoma, Hepatocellular, sponsored by Tannaz Armaghnay.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 5
- Study locations
NCT03253289: Completed Phase 1 study of Carcinoma, Hepatocellular, sponsored by Tannaz Armaghnay.
NCT03253289 is a Phase 1 study of Carcinoma, Hepatocellular that has completed, run by Tannaz Armaghnay. The registered enrollment target is 13 participants, below the 612-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03253289, a Phase 1 study of Carcinoma, Hepatocellular, has completed, sponsored by Tannaz Armaghnay.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 5
- Study locations
Study Summary
Meclizine hydrochloride is an antihistamine widely used for treatment of vertigo and motion sickness. In HCC it has been used for anti-emetic effects, but it is used here as a CAR (constitutive androstane receptor) inverse agonist. The hypothesis of this study is that Meclizine, CAR inverse agonist, will have beneficial therapeutic effect in patients with hepatocellular carcinoma who are candidates for surgical resection, ablation, TACE, Y90 or systemic therapy by blocking tumorigenesis and inducing apoptosis. The effects of Meclizine will be analyzed by measuring messenger RNA level of CAR target genes CYP2B6, c-Myc and FoxM1, the downstream effectors of CAR, by real time quantitative PCR.
Primary Outcome
Quantitative real time PCR(qPCR) can give change in expression level compared to control Delta CT value. Downstream target genes of CAR (CYP2b6,c-Myc, and FoxM) will be measured by qPCR in the pre and post treatment Hepatocellular cancer tissue specimens. The qPCR machine measures the intensity of fluorescence emitted by the probe at each cycle. The Ct measure is a determined PCR cycle and represents the basic result of a qPCR experience. The Ct is the value where the PCR curve crosses the thres
Conditions Studied
Interventions
- DRUG Meclizine Oral Tablet
Study Locations (5)
Texas
- Baylor College of Medicine -McNair Campus - Houston
- Baylor College of Medicine - Houston
- Baylor St. Luke's Medical Center - Houston
- Ben Taub General Hospital - Houston
- Harris Health System- Smith Clinic - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-10-13 |
| Est. Completion | 2023-03-28 |
| Phase | Phase 1 |
What the finished NCT03253289 record still lists
NCT03253289 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 612-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Carcinoma, Hepatocellular appearing as the primary indexed condition, and to 1 intervention - of which Meclizine Oral Tablet is the first listed.
NCT03253289 lists 5 locations in 1 state (Texas).
Frequently Asked Questions
What is clinical trial NCT03253289 about?
NCT03253289 is a clinical study titled "Meclizine for Hepatocellular Carcinoma". Meclizine hydrochloride is an antihistamine widely used for treatment of vertigo and motion sickness. In HCC it has been used for anti-emetic effects, but it is used here as a CAR (constitutive androstane receptor) inverse agonist. The hypothesis of this study is that Meclizine, CAR inverse agonist...
What is the current status of trial NCT03253289?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2017-10-13. Estimated completion is 2023-03-28.
What conditions does trial NCT03253289 study?
This clinical trial studies the following conditions: Carcinoma, Hepatocellular.
What interventions are being tested in trial NCT03253289?
The interventions under investigation include: Meclizine Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03253289?
This trial is sponsored by Tannaz Armaghnay, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03253289 being conducted?
This trial has 5 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Hepatocellular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03253289's enrollment target sits among peer trials
13 27th of 27 higher than 1 of 27 other Carcinoma, Hepatocellular trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Hepatocellular trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
RECRUITING · Phase 1
-
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
COMPLETED · Phase 1
-
Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors
COMPLETED · Phase 1
-
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI